Pre-Engraftment Syndrome after Unrelated Cord Blood Transplantation: A Predictor of Engraftment and Acute Graft-versus-Host Disease  by Park, Meerim et al.
Biol Blood Marrow Transplant 19 (2013) 640e646American Society for Blood
ASBMT
and Marrow TransplantationPre-Engraftment Syndrome after Unrelated Cord Blood
Transplantation: A Predictor of Engraftment and Acute
Graft-versus-Host Disease
Meerim Park 1, Soo Hyun Lee 2, Young Ho Lee 3,*, Keon Hee Yoo 2,
Ki Woong Sung 2, Hong Hoe Koo 2, Hyoung Jin Kang 4, Kyung Duk Park 4,
Hee Young Shin 4, Hyo Seop Ahn 4, Nak Gyun Chung 5, Bin Cho 5,
Hack Ki Kim 5, Kyung Nam Koh 6, Ho Joon Im6, Jong Jin Seo 6,
Dong Kyun Han 7, Hee Jo Baek 7, Hoon Kook 7, Tai Ju Hwang 7, EunKyung Lee 8,
Jeong Ok Hah 8, Yeon Jung Lim 9, Hyun Joo Jung 10, Jun Eun Park 10,
Moon Ju Jang 11, So Young Chong 11, Doyeun Oh11, on behalf of the Korean Cord
Blood Transplantation Working Party
1Department of Pediatrics, Chungbuk National University College of Medicine, Cheongju, Korea
2Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
3Department of Pediatrics, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Korea
4Department of Pediatrics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
5Department of Pediatrics, Seoul St.Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
6Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
7Department of Pediatrics, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Gwangju,
Korea
8Department of Pediatrics, Yeungnam University, Daegu, Korea
9Department of Pediatrics, Chungnam National University, Daejon, Korea
10Department of Pediatrics, Ajou University School of Medicine, Suwon, Korea
11Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam, KoreaArticle history:
Received 1 November 2012
Accepted 16 January 2013
Key Words:
Pre-engraftment syndrome
Cord blood transplantation
Risk factor
OutcomeFinancial disclosure: See Acknowl
* Correspondence and reprint
Department of Pediatrics, Hanyan
University College of Medicine, W
Korea.
E-mail address: cord@hanyang.
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Pre-engraftment syndrome (PES) is poorly characterized, and its clinical signiﬁcance and the prognostic
impact after unrelated cord blood transplantation (CBT) are unclear. To address these issues, we retrospec-
tively analyzed the incidence, risk factors, and clinical outcomes of PES in unrelated CBT recipients. Data of
381 patients who received unrelated CBT from 18 medical centers in Korea were reviewed. PES was deﬁned as
unexplained fever >38.3C not associated with infection, and/or unexplained skin rash with or without
evidence of ﬂuid retention before neutrophil recovery. PES developed in 102 patients (26.8%) at a median of 7
days after CBT. Of these patients, 74 patients (72.5%) received intravenous corticosteroid at a median dose of 1
mg/kg/day, and of these, 95% showed clinical improvement. Risk factors for developing PES included low risk
disease, myeloablative conditioning, graft-versus-host disease (GVHD) prophylaxis without methotrexate or
corticosteroid, and >5.43 x 107/kg infused nucleated cells. Absence of PES was one of the risk factors for graft
failure in multivariate analysis. The cumulative incidence of grade II to grade IV acute GVHD by 100 days after
CBT was higher in patients with PES than in those without PES (56.0% versus 34.4%, P < .01). PES was not
associated with chronic GVHD, treatment-related mortality, relapse, or overall survival. PES seems to be
common after CBT and may be associated with enhanced engraftment without signiﬁcant morbidity.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION PES is commonly characterized by noninfectious fever and
Cord blood transplantation (CBT) is a promising approach
in patients for whom a sibling or matched unrelated donor is
not available [1-3]. Post-transplantation immune disorders,
including pre-engraftment syndrome (PES), engraftment
syndrome, and acute graft-versus-host disease (GVHD) are
problematic in CBT. The complex and intricate pathophysi-
ology of post-transplantation immune disorders is a conse-
quence of interactions between the donor and host innate
and adaptive immune responses. PES, a clinical entity of
unknown pathogenesis, has been described in patients
receiving CBT [4-6]. Although a uniform deﬁnition is lacking,edgment on page 645.
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13.01.014various other clinical ﬁndings before neutrophil engraftment,
including skin rash, pulmonary inﬁltrates, diarrhea, jaundice,
or weight gain. To date, PES is an entirely clinical entity with
no known pathognomonic histopathologic changes or
biochemical markers. Kishi et al. [4] were the ﬁrst to report
a pre-engraftment immune reaction, which occurred in 35 of
45 adult recipients of reduced-intensity conditioning CBT.
However, PES still remains poorly characterized and its
clinical signiﬁcance and the prognostic impact after CBT are
unclear. To address these issues, we retrospectively analyzed
the incidence, risk factors, and clinical outcomes of PES in
unrelated CBT recipients enrolled in a multicenter CBT trial.MATERIALS AND METHODS
Patient and Transplantation Characteristics
The clinical data of 381 cases of unrelated CBT performed at 18 trans-
plantation centers in Korea between 2000 and 2010 were reviewedTransplantation.
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the Korean Cord Blood Transplantation Registry, and the data were veriﬁed
by comparing the reports with the primary data sources. This study was
approved by the Institutional Review Board of Hanyang University Medical
Center. Informed consent was obtained from the patients and/or guardians
before CBT. The characteristics of patients and transplantation are listed in
Table 1. Reduced-intensity regimens were generally deﬁned as reported
previously [7,8].
Acute leukemia in ﬁrst complete remission (CR), chronic myelogenous
leukemia in the chronic phase, malignant lymphoma in CR, multiple
myeloma in CR, myelodysplastic syndrome in refractory anemia, and
nonmalignant diseases were deﬁned as low risk, whereas all other malig-
nant diseases were considered high risk. Patients who underwent previous
hematopoietic stem cell transplantationwere also classiﬁed in the high-risk
group.
Deﬁnitions
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an absolute neutrophil count>0.5 x 109/L. Graft failure (GF) comprised
2 clinical entities: (1) failure to achieve an absolute neutrophil count of 0.5 x
109/L and marrow hypoplasia for fewer than 60 days with or without the
existence of donor type hematopoiesis, and (2) complete loss of donor-type
hematopoiesis at any time after transplantation. Late GF was deﬁned as the
loss of the graft during follow-up. Both acute and chronic GVHDwere graded
according to the previously published criteria [9,10]. Cytomegalovirus (CMV)
infection was deﬁned as positive pp65 CMV antigenemia, deﬁned as 1
antigen-positive cell in a single slide. CMV disease was deﬁned as end-organ
disease, such as pneumonia, gastrointestinal disease, hepatitis, etc., with
a documented CMV etiology [11]. Transplantation-related mortality (TRM)
was deﬁned as any death not the result of relapse, progression, or persis-
tence of the underlying disease.
Following the criteria of Patel et al. [12], PES was deﬁned as unexplained
fever >38.3C not associated with documented infection and/or an unex-
plained erythematous skin rash resembling that of acute GVHD, with eitherTable 1
Characteristics of Patients and Cord Blood Transplantation
Variables Number of Patients
(N ¼ 381)
Age, years, median (range) 7.2 (0.3-65.4)
Weight, kg, median (range) 23.4 (6.1-89.7)
Gender, n
M:F 221:160
Primary disease, n
Malignant disease 314
Acute lymphoblastic leukemia 127
Acute myeloid leukemia 135
Myelodysplastic syndrome 13
Chronic myelogenous leukemia 20
Nonmalignant disease 67
Aplastic anemia 11
Others 56
Previous transplantation, n 33
Autologous:allogeneic 16:17
Preparative regimen, n
Myeloablative:reduced-intensity 261:120
In vivo T cell depletion, n
ATG 259
Other than ATG 14
None 108
CMV serostatus (n ¼ 294)
Positive:Negative 269:25
No. of infused nucleated cells, median (range),
107/kg
5.10 (0.27-104.4)
No. of infused CD34þ cells, median (range),
105/kg
2.08 (0.08-61.6)
No. of donors
One:Two 225:156
HLA match (A/B/DR, antigen level, lowest)*, n
6/6 27
5/6 176
4/6 127
3/6 48
ATG indicates antithymocyte globlulin; CMV, cytomegalovirus.
* HLAmatch equals the poorest matched unit in recipients of 2 cord blood
units.the fever or the rash occurring before or at neutrophil recovery. Speciﬁcally,
fever attributed to PES was not associated with any clinical evidence of
infection, with patients having both a negative infectious disease workup
and a continued lack of response to broad-spectrum antimicrobial agents.
Erythematous skin rash attributed to PES was not associated with any
clinical suspicion of drug allergy.Weight gainwas deﬁned as a 3% increase in
body weight between the day of CBT and the onset of PES. Noninfectious
diarrhea was deﬁned as passage of watery stools more than twice a day for
at least 3 consecutive days with no evidence of infectious etiology. Treat-
ment of the PES was at the physicians’ discretion.
Statistical Analysis
Categorical variables were compared using the chi-square test and
continuous variables using the Mann-Whitney U test. The cumulative inci-
dence rates of neutrophil recovery, GVHD, infections, relapse, and TRMwere
calculated and compared using Gray’s method. For neutrophil engraftment,
the competing risks were autologous recovery, infusion of a backup graft, or
death. GF and death were the competing events for GVHD, whereas relapse
was the competing event for TRM. Prognostic factors for the occurrence of
PES, GF, GVHD, and survival were evaluated using Cox regression analysis.
Overall survival (OS) was the time between day 0 of cord blood infusion and
death from any cause, and living patients were censored at last follow-up.
Survival was calculated by the Kaplan-Meier method and the difference in
survival rates based on PES classiﬁcationwas determined using the log-rank
test. Factors signiﬁcant at the 0.1 level on univariate analysis were consid-
ered for multivariate analyses using backward elimination. Two-sided P
values less than .02 were considered signiﬁcant. All analyses were con-
ducted using SPSS version 18.0 software and R version 2.10.1.
RESULTS
Incidence and Clinical Characteristics of PES
Of 381 patients, 102 patients (26.8%) fulﬁlled the diag-
nostic criteria for PES. Fever of otherwise unexplained
etiology was present in 93.9% of transplantation patients
diagnosed with PES, an erythematous skin rash in 81.8%, C-
reactive protein elevation in 52.8%, diarrhea in 29.3%, weight
gain>3% of baseline bodyweight in 27.3%, pulmonary edema
in 13.3 %, and central nervous system symptoms in 8.0%.
Hypoxia due to noncardiogenic pulmonary edema was
identiﬁed in 8.7% of the PES patients. The ﬁrst manifestation
of PES was an unexplained fever with a median onset of 7
days (range, 3 to 41) after CBT, followed by skin rashes at day
10 (range, 2 to 34). The onset of PES occurred at a median of
11 days before neutrophil engraftment and was not signiﬁ-
cantly associated with any clinical variables. PES was also
observed in 6 patients who had never engrafted.
Histologic examinations of skin were conducted in 10
patients (9.8%). Common ﬁndings were perivascular
lymphocytic inﬁltration (n ¼ 5) and vacuolization in the
basal layer (n ¼ 3).
Of all patients who developed PES, 28 patients (27.5%)
showed clinical improvement with only supportive care,
such as ﬂuid restriction and the use of diuretics. Seventy-four
patients (72.5%) received intravenous corticosteroid at
a median dose of 1 mg/kg/day (range, 0.1 to 10) for a median
of 7 days (range, 2 to 58). Compared to the patients whose
PES resolved without corticosteroid therapy, those who
received corticosteroid showed signiﬁcantly earlier onset of
fever (7 days versus 11 days, P < .01) and a higher incidence
of weight gain >3% of baseline body weight (35.7% versus
10.7%, P ¼ .01). Approximately 95% of the patients who
received corticosteroid therapy because of PES showed
clinical improvement. Three patients were steroid-
refractory. These 3 patients died of PES itself, acute GVHD,
or infection within 60 days of CBT.
Risk Factors for PES
Table 2 outlines the patient demographics and graft
characteristics of the 102 patients with PES and the 279
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analysis, low-risk disease, myeloablative conditioning, GVHD
prophylaxis without methotrexate or corticosteroid, and
infused total nucleated cells (TNC) >5.43 x 107/kg were
signiﬁcant risk factors for PES (Table 3).PES and Engraftment
GF occurred in 78 patients (20.5%): primary GF in 49
patients, late GF in 7 patients, and autologous recovery in 22
patients. Of the 102 patients with PES, 95 patients showed
successful engraftment. The median time to neutrophil
engraftment was 18 days (range, 7 to 84 days) for patients
without PES and 19 days (range, 9 to 92) for those with PES.
In a multiple logistic regression analysis, absence of PES was
a signiﬁcant risk factor for GF (RR, 5.50; 95% CI, 2.24 to 13.49,
P< .01). Among the patients who experienced PES, there was
no signiﬁcant difference in the incidence of GF depending on
steroid use (P ¼ .34).PES and GVHD
The cumulative incidence of grade II to grade IV acute
GVHD in the entire group was 40.2%. PES was a signiﬁcant
risk factor for grade II to grade IV acute GVHD in multivariate
analysis (RR, 1.84; 95% CI, 1.11 to 3.06, P ¼ .02) after adjusting
for age, sex, weight, conditioning regimen, HLA match,
number of donors, and total cell counts.Table 2
Comparison of Transplantation Characteristics in Patients with and Without Pre-E
Variables PES (n
Age, year, median (range) 6.3 (0.5
Weight, kg, median (range) 19.1 (6
Double unit CBT, n 51
Disease category, n
Malignant disease 81
Nonmalignant disease 21
Salvage CBT, n 3
Disease risk, n
High risk 22
Low risk 79
HLA match (A/B/DR, antigen level, lowest)*, n
5-6/6 48
4/6 38
3/6 15
Conditioning regimen, n
Myeloablative 86
Reduced-intensity 16
In vivo T cell depletion, n
Yes 62
No 40
Total body irradiation in conditioning, n
Yes 36
No 66
GVHD prophylaxis with MTX, n
Yes 4
No 98
GVHD prophylaxis with steroid, n
Yes 20
No 82
CMV serostatus (n ¼ 294)
Positive 65
Negative 2
No. of infused nucleated cells, (107/kg), median (range) 6.28 (1
>5.43 58
5.43 33
No. of infused CD34þ cells, (105/kg), median (range) 2.55 (0
>1.60 76
1.60 20
CBT indicates cord blood transplantation; GVHD, graft versus host disease; MTX, m
* HLA match equals the poorest matched unit in recipients of 2 cord blood unitThe cumulative incidence rates of grade II to grade IV
acute GVHD by 100 days after CBT in patients with and
without PES were 56.0% and 34.4%, respectively (P < .01).
Among the patients with PES, there was a negative correla-
tion between the day of PES development and the incidence
of acute GVHD (P ¼ .04). That is, those in whom PES occurred
earlier had a higher incidence of grade II to grade IV acute
GVHD. Patterns of organ involvement were similar in PES
and acute GVHD. Grade II to grade IV acute GVHD skin
involvement was more frequent in patients with skin
manifestations during the course of PES than in those
without such manifestations (RR, 2.97; 95% CI, 1.03 to 8.51,
P¼ .04). Patients who showed hyperbilirubinemia during the
period of PES suffered a signiﬁcantly higher incidence of
acute liver GVHD grade II (RR, 4.63; 95% CI, 1.36 to 15.7,
P ¼ .01). However, the incidence of acute gastrointestinal
GVHD grade II did not differ signiﬁcantly in patients with
and without diarrhea during the clinical course of PES.
The cumulative incidence of chronic GVHD was 20.9% by
one year after CBT. The incidence and severity of chronic
GVHD did not differ signiﬁcantly in patients with and
without PES.PES and Transplantation Outcomes
Patients with PES had a higher incidence of early bacterial
infection (28 days after CBT) than those without PES (21.0%
versus 12.6%, P ¼ .05). The incidence of early bacterialngraftment Syndrome (PES)
¼ 102) No PES (n ¼ 279) Univariate P
-48.8) 7.5 (0.5-65.4) .07
.2-73.0) 24.5 (6.1-89.7) <.01
105 .03
.36
233
46
30 .014
<.01
121
151
.06
155
89
33
<.01
175
104
<.01
211
68
.54
90
189
.04
30
249
<.01
117
162
.08
204
23
.45-31.3) 4.73 (0.27-104.4) <.01
110
155
.4-26.9) 1.84 (0.08-61.6) <.01
149
111
ethotrexate; CMV, cytomegalovirus.
s.
Table 3
Signiﬁcant Risk Factors for Pre-Engraftment Syndrome in the Multivariate
Analysis
Variables HR 95% CI P Value
Disease risk .02
High risk 1
Low risk 2.00 1.01-3.64
Conditioning regimen <.01
Reduced-intensity 1
Myeloablative 6.14 3.28-12.24
GVHD prophylaxis with MTX .03
Yes 1
No 5.35 1.16-24.68
GVHD prophylaxis with steroid <.01
Yes 1
No 5.01 2.63-9.54
No. of infused nucleated cells, (107/kg) <.01
5.43 1
>5.43 2.08 1.21-3.59
HR indicates hazard ratio; GVHD, graft-versus-host disease; MTX,
methotrexate.
Figure 1. Overall survival in patients with and without pre-engraftment
syndrome.
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PES (P ¼ .07). No patients who received 1 mg/kg/day of
intravenous corticosteroid for 7 days (median dose and
duration of PES treatment demonstrated in this study)
experienced early bacterial infection. However, higher dose
(P < .01) and prolonged use (P ¼ .04) of steroid were asso-
ciated with early bacterial infection.
A higher incidence of CMV infectionwas found in patients
with PES than in those without PES (57.4% versus 42.5%, P ¼
.01). However, the prevalence of CMV disease did not differ
between the 2 groups (P ¼ .27).
After a median follow-up of 74 months, the 5-year OS of
all patients was 49.2%  2.7%. In a multivariate analysis,
factors associated with poor survival included total body
irradiation-based conditioning regimen, CMV disease and
low infused CD34þ cell dose (Table 4). OS did not differ
depending on the presence or absence of PES after CBT
(Figure 1). Likewise, TRM by 3 years after CBT was not
signiﬁcantly different in the 2 groups (Figure 2). In patients
with malignancies, the cumulative incidence of relapse 3
years after CBT was 31.7% in patients without PES and 16.9%
in patients with PES (Figure 3). In summary, we could not
identify any impact of the occurrence of PES on OS, TRM, or
relapse.
DISCUSSION
To our knowledge, this is the largest study to date eval-
uating PES occurring after CBT. Many studies have reported
that CBT recipients often develop immune reactions before
neutrophil engraftment [6,12,13]. Recently, several groupsTable 4
Signiﬁcant Prognostic Factors for Overall Survival in the Multivariate
Analysis
Variables HR 95% CI P Value
Total body irradiation in conditioning <.01
No 1
Yes 1.74 1.27-2.38
CMV disease .01
No 1
Yes 1.60 1.09-2.34
No. of infused CD34þ cells, (105/kg) .02
>1.60 1
1.60 1.23 1.00-1.58
HR indicates hazard ratio; CMV, cytomegalovirus.classiﬁed post-CBT immune reactions in relation to the time
to neutrophil engraftment as follows: PES or pre-
engraftment immune reactions, engraftment syndrome,
and acute GVHD (postengraftment immune reaction)
[4,6,14]. The incidence of PES following CBT has been re-
ported as 20% to 70% [4,13]. Although PES is a clinical entity
described in patients receiving CBT, Lee et al. [5] have re-
ported that its incidence does not depend on the source of
the graft. In our study, PES occurred in 26.8% of patients.
Onset of PES in our CBT patient series was a median of 11
days before neutrophil recovery, clearly justifying the term
“pre-engraftment”. Interestingly, PES also developed in someFigure 2. Treatment related mortality in patients with and without pre-
engraftment syndrome.
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the mechanism of PES differs from that of engraftment
syndrome or GVHD. Furthermore, the median time to
neutrophil engraftment did not differ in patients with and
without PES. On the basis of these ﬁndings and other studies
[15,16], we suggest that PES is induced by cytokine storms
due to cytokines that already existed in the donor cord blood
cells. That is, PES may be a response of recipients to the
infused cord blood cells, whereas the known mechanism of
GVHD involves an interaction of engraftment-driven
lymphocytes with recipient tissues.
In our analysis, high numbers of CD34þ cells/kg and TNC/
kg were signiﬁcantly associated with PES. In multivariate
analysis, high TNC count remained signiﬁcant, but number of
CD34þ cells did not. This ﬁnding also supports a role of CB
mononuclear cells such as lymphocytes in the development
of PES.
As shown in this study, the fact that GVHD prophylaxis
can inﬂuence the incidence of PES suggests that PES may be
caused by immunologic reactivity, and this interpretation is
supported by the fact that PES patients who were treated
responded very well to intravenous corticosteroid. Further-
more, steroid prophylaxis decreased the incidence of PES
almost 5-fold in our study. The beneﬁcial effects of steroid
therapy may derive from its immunosuppressive effect on
cytokine reactions as well as its anti-inﬂammatory action.
PES supposedly develops in conjunction with cytokine
storms or proliferation of naïve T cells in cord blood [4,17].
Parenchymal tissue may be sensitized to the potentially
toxic effects of transplantation conditioning by previous
therapy, which would tend to aggravate inﬂammation.
Immunological phenomena during the pre-engraftment
period may be inﬂuenced by proinﬂammatory cytokines
produced soon after the conditioning therapy. At the time
of transplantation, patients with advanced disease may
be relatively depleted of important cellular populations
(eg, tissue macrophages, B cells) that contribute to inﬂam-
mation during transplantation and thus may be at decreased
risk of producing inﬂammatory cytokines during condi-
tioning [18,19]. This concept is supported by the evidence
for lower post-transplantation inﬂammatory cytokine
levels in the recipients pretreated with chemotherapy [18]
and the enhanced inﬂammatory cytokine levels seen inFigure 3. Cumulative incidence of relapse in patients with and without pre-
engraftment syndrome.chemotherapy-naïve patients undergoing transplantation
[20,21]. Therefore, low-risk patients with enhanced inﬂam-
matory cytokine levels could provoke more severe inﬂam-
matory response to the infused CB cells than high-risk
patients. This hypothesis supports our ﬁnding that patients
with low-risk diseases are at risk of PES.
In our study, patients who did not experience PES had
a higher incidence of GF than patients with PES. Wang et al.
[22] similarly reported that the cumulative incidence of
engraftment in patients with PES was 91.9% compared with
76.7% in those without PES. Frangoul et al. [6] also reported
that the cumulative incidence of neutrophil engraftment in
patients with PES was 84% compared with 77% in those
without PES. Although the rates of engraftment in patients
with PES in these 2 studies were higher, the corresponding P
values did not reach statistical signiﬁcance, perhaps due in
part to small sample sizes or baseline differences in trans-
plantation characteristics. The complex interplay of the bone
marrow microenvironment with the cytokines of the inter-
acting cells, which occurs during PES, may be associated with
neutrophil regeneration during the early post-
transplantation period [14,23]. Recently, Takahashi et al.
[15] found that the levels of various proinﬂammatory cyto-
kines such as TNFa, IL-1b, IL-6, and IFNg, are strongly inter-
related. Interestingly, concentrations of IL-8, which is
integral to neutrophil regeneration and function [24,25],
were highly correlated with levels of proinﬂammatory
cytokines and G-CSF. Furthermore the levels of these proin-
ﬂammatory cytokines were also strongly correlated with
those of growth factors (eg, G-CSF and GM-CSF). In addition,
accumulating evidence supports an essential role of IL-6 in
the development, differentiation, and regeneration of stem
cells [26,27]. These ﬁndings support the hypothesis that PES
affects engraftment by an indirect mechanism.
We observed a close relation between PES and the
development of grade II to grade IV acute GVHD but not
chronic GVHD. This association raises the possibility that PES
represents an early form of acute GVHD. The propensity of
acute GVHD in PES to target organs with environmental
interfaces and thus potentially with previously damaged
organs may not be coincidental. Since cytokine release and
hyperinﬂammation are hallmarks of both PES and acute
GVHD, one may speculate that there is some overlap
between the 2 syndromes. However, the association of PES
with chronic GVHD seems different from its relationship
with acute GVHD. It appears that autoantibodies and B cells
contribute to chronic GVHD process through the simulation
of ﬁbrosis [28,29]. Chronic GVHD itself does not appear to be
proinﬂammatory state, unlike acute GVHD and PES. There-
fore, one would not anticipate any signiﬁcant association
between PES and chronic GVHD.
We observed that PES was associated with increased rates
of early bacterial infection and CMV infection. The increased
risk of clinical infection in PES may be associated with
cytokine dysregulation and impaired immunomodulatory
function. In addition, immunosuppressive therapy may
increase the risk of infection. Where PES is clinically severe,
additional steroid treatment may be inevitable in some
patients.We found that corticosteroid use due to PES was not
a signiﬁcant risk factor for infection in CBT. However, higher
doses or prolonged use of steroid can be signiﬁcant risk
factors for infection. Prompt recognition of PES and treat-
ment with a short-course corticosteroid regimen, if needed,
could help to avoid unnecessarily long, empiric courses of
treatment that could promote opportunistic infections.
M. Park et al. / Biol Blood Marrow Transplant 19 (2013) 640e645 645In this study, as in others [6,12,22], PES did not have
a negative impact on survival or transplantationerelated
death. This contrasts with the adverse survival impact of
hyperacute or pre-engraftment GVHD in unrelated bone
marrow or peripheral blood stem cell transplantation
[30,31]. It seems that there are some differences between PES
after CBT and hyperacute or pre-engraftment GVHD after
transplantation using bone marrow or peripheral blood.
Factors that may contribute to the relatively benign clinical
course of PES after CBT may include reduced graft lympho-
cyte numbers, fewer T cells interacting with recipient’s
antigen-presenting cells, and limited responses of naïve T
cells to recipient alloantigen [32-34]. Other explanations
may include the possibility that the PES was sufﬁciently
manageable to not affect survival in cases of CBT. In our
series, most of patients with PES responded well to steroid.
Nevertheless, close observation of patients with PES is
required because some patients deteriorate and are refrac-
tory to steroids, as shown in this study.
In conclusion, PES seems to be common after CBT and
may be associated with enhanced engraftment. Although
PES is closely associated with acute GVHD, PES after CBT is
not associated with signiﬁcant morbidity and is easily
manageable with intravenous steroid. Because failure to
recognize PES in CBT recipient risks unnecessary complica-
tions of this syndrome and unnecessarily long, empirical
treatment, physicians should be aware of the possible
occurrence of PES after CBT, especially in patients who have
relevant risk factors for developing PES.
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